Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Bansal, Dipika ^a   Undela, Krishna ^a   D'Cruz, Sanjay ^b   Schifano, Fabrizio ^c  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ADVANCED CANCER; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREND STUDY;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, STATISTICAL; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84866991538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046691     Document Type: Article

References (57)

1. World Health Organization (2011) CancerStats Cancer worldwide. Available: http://info.cancerresearchuk.org/cancerstats/world/. Accessed Jan 22 2011.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. National Cancer Institute (2011) SEER stat fact sheets: Prostate. Available: http://seer.cancer.gov/statfacts/html/prost.html. Accessed Jan 22 2011.
4. Oh HY, Leem J, Yoon SJ, Yoon S, Hong SJ, (2010) Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Biochem Biophys Res Commun 393: 319-324.
5. Murtola TJ, Tammela TL, Mllttlnen L, Huhtala H, Platz EA, et al. (2010) Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 127: 1650-1659.
6. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Ga]iano JM, (2011) Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 103: 885-892.
7. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG, (2011) Statin use and fatal prostate cancer: A matched case-control study. Cancer In press.
8. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, et al. (2007) Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 16: 2218-2225.
9. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, et al. (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114: 643-647.
10. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, et al. (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819-1825.
11. Lovastatin Study Groups I through IV (1993) Lovastatin 5-year safety and efficacy study. Arch Intern Med 153: 1079-1087.
12. Kaye JA, Jick H, (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90: 635-637.
13. Sato S, Ajiki W, Kobayashi T, Awata N, (2006) Group PS (2006) Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16: 201-206.
14. Murtola TJ, Tammela TL, Lahtela J, Auvinen A, (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16: 2226-2232.
15. Blais L, Desgagné A, LeLorier J, (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368.
16. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ, (2004) The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394.
17. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, et al. (2005) Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162: 318-325.
18. Heart Protection Study Collaborative Group (2005) The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 3: 6.
19. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, et al. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357: 1477-1486.
20. ClinicalTrials.gov (2011) Simvastatin therapy versus placebo prior to prostatectomy. Available: http://clinicaltrials.gov/ct2/show/NCT00572468?term=simvastatinANDprostatecancer&rank=1. Accessed Jan 22 2011.
21. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM, (2006) Statins and cancer risk: a meta-analysis. JAMA 295: 74-80.
22. Browning DR, Martin RM, (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120: 833-843.
23. Kuoppala J, Lamminpaa A, Pukkala E, (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44: 2122-2132.
24. Bonovas S, Filioussi K, Sitaras NM, (2008) Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123: 899-904.
25. Boudreau DM, Yu O, Buist DS, Miglioretti DL, (2008) Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19: 767-774.
26. Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, et al. (2010) The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol 184: 494-499.
27. Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ, (2010) Is statin use associated with prostate cancer aggressiveness? BJU Int 105: 1222-1225.
28. Tan N, Klein EA, Li J, Moussa AS, Jones JS, (2011) Statin use and risk of prostate cancer in a population of men who underwent biopsy. J Urol 186: 86-90.
29. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, et al. (2011) Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 185: 1268-1273.
30. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, et al. (2010) Incidence of cancer and statin usage-record linkage study. Int J Cancer 126: 279-284.
31. Coogan PF, Kelly JP, Strom BL, Rosenberg L, (2010) Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 19: 752-755.
32. Chang CC, Ho SC, Chiu HF, Yang CY, (2011) Statins increase the risk of prostate cancer: a population-based case-control study. Prostate 71: 1818-1824.
33. Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, et al. (2011) The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control 22: 417-426.
34. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, et al. (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17: 27-36.
35. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S, (2008) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67: 99-109.
36. Hippisley-Cox J, Coupland C, (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340: c2197.
37. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL, (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168: 250-260.
38. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM, (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71: 1763-1771.
39. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, et al. (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13: 262-267.
40. Coogan PF, Rosenberg L, Strom BL, (2007) Statin use and the risk of 10 cancers. Epidemiology 18: 213-219.
41. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, et al. (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16: 2213-2217.
42. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, et al. (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100: 134-139.
43. Ottawa Hospital Research Institute (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Jan 22 2011.
44. Zhang J, Yu KF, (1998) What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280: 1690-1691.
45. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
46. Egger M, Davey SG, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
47. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
48. Altman DG, Bland JM, (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
49. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
50. Solomon KR, Freeman MR, (2011) The Complex Interplay Between Cholesterol and Prostate Malignancy. Urol Clin North Am 38: 243-259.
51. Boudreau DM, Yu O, Johnson J, (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9: 603-621.
52. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM, (2005) Statins and cancer prevention. Nat Rev Cancer 5: 930-942.
53. Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y, et al. (2010) Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev 3: 114-124.
54. Murtola TJ, Pennanen P, Syvlll H, Blluer M, Ylikomi T, et al. (2009) Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 69: 1017-1023.
55. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA, (2010) Association between Plasma Total Cholesterol Concentration and Incident Prostate Cancer in the CLUE II Cohort. Cancer Causes Control 21: 61-68.
56. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ, (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100: 1511-1518.
57. Buschemeyer WC, Freedland SJ, (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52: 331-343.